<SEC-DOCUMENT>0002005369-25-000052.txt : 20251002
<SEC-HEADER>0002005369-25-000052.hdr.sgml : 20251002
<ACCEPTANCE-DATETIME>20251002170459
ACCESSION NUMBER:		0002005369-25-000052
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20251002
DATE AS OF CHANGE:		20251002

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TENAX THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0000034956
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				262593535
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-58467
		FILM NUMBER:		251370492

	BUSINESS ADDRESS:	
		STREET 1:		101 GLEN LENNOX DRIVE
		STREET 2:		SUITE 300
		CITY:			CHAPEL HILL
		STATE:			NC
		ZIP:			27517
		BUSINESS PHONE:		919-855-2100

	MAIL ADDRESS:	
		STREET 1:		101 GLEN LENNOX DRIVE
		STREET 2:		SUITE 300
		CITY:			CHAPEL HILL
		STATE:			NC
		ZIP:			27517

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	OXYGEN BIOTHERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20080703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SYNTHETIC BLOOD INTERNATIONAL INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SINEQUANON CORP
		DATE OF NAME CHANGE:	19901219

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Invus Global Management, LLC
		CENTRAL INDEX KEY:			0002005369
		ORGANIZATION NAME:           	
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G

	BUSINESS ADDRESS:	
		STREET 1:		THE INVUS GROUP, LLC
		STREET 2:		750 LEXINGTON AVENUE, 30TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
		BUSINESS PHONE:		212-371-1717

	MAIL ADDRESS:	
		STREET 1:		THE INVUS GROUP, LLC
		STREET 2:		750 LEXINGTON AVENUE, 30TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: Invus Global Management, LLC -->
          <cik>0002005369</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>


    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <securitiesClassTitle>Common Stock, $0.0001 par value per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>09/26/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0000034956</issuerCik>
        <issuerName>Tenax Therapeutics, Inc.</issuerName>
        <issuerCusip>88032L605</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>101 Glen Lennox Drive</com:street1>
          <com:street2>Suite 300</com:street2>
          <com:city>Chapel Hill</com:city>
          <com:stateOrCountry>NC</com:stateOrCountry>
          <com:zipCode>27517</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Invus Public Equities, L.P.</reportingPersonName>
      <citizenshipOrOrganization>D0</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>366143.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>366143.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>366143.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>8.0</classPercent>
      <typeOfReportingPerson>PN</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Invus Public Equities Advisors, LLC</reportingPersonName>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>366143.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>366143.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>366143.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>8.0</classPercent>
      <typeOfReportingPerson>OO</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Invus Global Management, LLC</reportingPersonName>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>366143.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>366143.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>366143.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>8.0</classPercent>
      <typeOfReportingPerson>OO</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Siren, L.L.C.</reportingPersonName>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>366143.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>366143.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>366143.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>8.0</classPercent>
      <typeOfReportingPerson>OO</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>Avicenna Life Sci Master Fund LP</reportingPersonName>
      <citizenshipOrOrganization>E9</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>60998.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>60998.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>60998.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>1.3</classPercent>
      <typeOfReportingPerson>PN</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>Avicenna Life Sci Master GP LLC</reportingPersonName>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>60998.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>60998.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>60998.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>1.3</classPercent>
      <typeOfReportingPerson>OO</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Ulys, L.L.C.</reportingPersonName>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>60998.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>60998.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>60998.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>1.3</classPercent>
      <typeOfReportingPerson>OO</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Raymond Debbane</reportingPersonName>
      <citizenshipOrOrganization>R1</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>427141.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>427141.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>427141.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>9.4</classPercent>
      <typeOfReportingPerson>IN</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Tenax Therapeutics, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>101 Glen Lennox Drive, Suite 300, Chapel Hill, NC 27517</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>See Item 2(c) below.</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>See Item 2(c) below.</principalBusinessOfficeOrResidenceAddress>
        <citizenship>(i) Invus Public Equities, L.P. ("Invus Public Equities")
750 Lexington Avenue, 30th Floor, New York, NY 10022
Citizenship: Bermuda limited partnership

(ii) Invus Public Equities Advisors, LLC ("Invus PE Advisors")
750 Lexington Avenue, 30th Floor, New York, NY 10022
Citizenship: Delaware limited liability company

(iii) Invus Global Management, LLC ("Global Management")
750 Lexington Avenue, 30th Floor, New York, NY 10022
Citizenship: Delaware limited liability company

(iv) Siren, L.L.C. ("Siren")
c/o The Invus Group, LLC, 750 Lexington Avenue, 30th Floor, New York, NY 10022
Citizenship: Delaware limited liability company

(v) Avicenna Life Sci Master Fund LP ("Avicenna Fund")
750 Lexington Avenue, 30th Floor, New York, NY 10022
Citizenship: Cayman Islands limited partnership

(vi) Avicenna Life Sci Master GP LLC ("Avicenna GP")
750 Lexington Avenue, 30th Floor, New York, NY 10022
Citizenship: Delaware limited liability company

(vii) Ulys, L.L.C. ("Ulys")
750 Lexington Avenue, 30th Floor, New York, NY 10022
Citizenship: Delaware limited liability company

(viii) Mr. Raymond Debbane
750 Lexington Avenue, 30th Floor, New York, NY 10022
Citizenship: Panama

The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>Each of the Reporting Persons may be deemed to be the beneficial owner of the shares of common stock, $0.0001 par value per share (the "Shares") of Tenax Therapeutics, Inc. (the "Issuer") listed on such Reporting Person's cover page.

As of October 2, 2025, Invus Public Equities directly held 366,143 Shares of the Issuer and Avicenna Fund directly held 60,998 Shares of the Issuer. Invus PE Advisors, as the general partner of Invus Public Equities, controls Invus Public Equities and, accordingly, may be deemed to beneficially own the Shares beneficially owned by Invus Public Equities. Global Management, as the managing member of Invus PE Advisors, controls Invus PE Advisors and, accordingly, may be deemed to beneficially own the Shares that Invus PE Advisors may be deemed to beneficially own. Siren, as the managing member of Global Management, controls Global Management and, accordingly, may be deemed to beneficially own the Shares that Global Management may be deemed to beneficially own. Avicenna GP, as the general partner of Avicenna Fund, controls Avicenna Fund and, accordingly, may be deemed to beneficially own the Shares beneficially owned by Avicenna Fund. Ulys, as the managing member of Avicenna GP, controls Avicenna GP and, accordingly, may be deemed to beneficially own the Shares that Avicenna GP may be deemed to beneficially own. Mr. Raymond Debbane, as the managing member of Siren and Ulys, controls Siren and Ulys and, accordingly, may be deemed to beneficially own the Shares that Siren and Ulys may be deemed to beneficially own.</amountBeneficiallyOwned>
        <classPercent>As of October 2, 2025, each of the Reporting Persons may be deemed to be the beneficial owner of the percentage of Shares listed on such Reporting Person's cover page. Calculations of the percentage of Shares beneficially owned are based on 4,562,500 Shares outstanding as of August 11, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 13, 2025.</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>See each cover page hereof.</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>See each cover page hereof.</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>See each cover page hereof.</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>See each cover page hereof.</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>Each of the Reporting Persons hereby makes the following certification:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>Invus Public Equities, L.P.</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Raymond Debbane</signature>
        <title>Raymond Debbane, President of Invus Public Equities Advisors, LLC, its general partner</title>
        <date>10/02/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Invus Public Equities Advisors, LLC</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Raymond Debbane</signature>
        <title>Raymond Debbane, President</title>
        <date>10/02/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Invus Global Management, LLC</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Raymond Debbane</signature>
        <title>Raymond Debbane, President</title>
        <date>10/02/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Siren, L.L.C.</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Raymond Debbane</signature>
        <title>Raymond Debbane, President</title>
        <date>10/02/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Avicenna Life Sci Master Fund LP</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Raymond Debbane</signature>
        <title>Raymond Debbane, Chief Executive Officer of Avicenna Life Sci Master GP LLC, its general partner</title>
        <date>10/02/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Avicenna Life Sci Master GP LLC</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Raymond Debbane</signature>
        <title>Raymond Debbane, Chief Executive Officer</title>
        <date>10/02/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Ulys, L.L.C.</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Raymond Debbane</signature>
        <title>Raymond Debbane, President</title>
        <date>10/02/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Raymond Debbane</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Raymond Debbane</signature>
        <title>Raymond Debbane</title>
        <date>10/02/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>

</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit991.htm
<DESCRIPTION>JOINT FILING AGREEMENT
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; background-color: white">Exhibit 99.1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center; background-color: white">JOINT FILING AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; background-color: white">The undersigned agree that the statement
on Schedule 13G with respect to the securities of Tenax Therapeutics, Inc. is, and any amendments thereto signed by each or any of the undersigned
shall be, filed on behalf of each of such person pursuant to, and in accordance with, the provisions of Rule&nbsp;13d-1(k)&nbsp;under
the Securities Exchange Act of 1934, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; background-color: white">Dated: 10/02/2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 3.5in 0 0"><B>INVUS PUBLIC EQUITIES, L.P.</B></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0 3.5in 0 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 3.5in 0 0">By:&#9;INVUS PUBLIC EQUITIES ADVISORS,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 3.5in 0 0; text-indent: 0.5in">LLC, its general partner</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0 3.5in 0 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">By: <U>/s/ Raymond Debbane&#9;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Name: Raymond Debbane</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 3.5in 0 0">Title:&#9;President</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 3.5in 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 3.5in 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 3.5in 0 0"><B>INVUS PUBLIC EQUITIES ADVISORS, LLC</B></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0 3.5in 0 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">By: <U>/s/ Raymond Debbane&#9;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Name: Raymond Debbane</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 3.5in 0 0">Title:&#9;President</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0 3.5in 0 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 3.5in 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>INVUS GLOBAL MANAGEMENT, LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 247.7pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">By: <U>/s/ Raymond Debbane&#9;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Name: Raymond Debbane</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Title: President</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 247.7pt 0 0"><B>SIREN, L.L.C.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 247.7pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">By: <U>/s/ Raymond Debbane&#9;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Name: Raymond Debbane</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Title: President</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 3.5in 0 0"><B>AVICENNA LIFE SCI MASTER FUND LP</B></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0 3.5in 0 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 3.5in 0 0">By:&#9;AVICENNA LIFE SCI MASTER GP LLC, its general partner</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0 3.5in 0 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">By: <U>/s/ Raymond Debbane&#9;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Name: Raymond Debbane</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 3.5in 0 0">Title:&#9;Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 247.7pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 247.7pt 0 0"><B>AVICENNA LIFE SCI MASTER GP LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 247.7pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">By: <U>/s/ Raymond Debbane&#9;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Name: Raymond Debbane</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Title: Chief Executive Officer</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 247.7pt 0 0"><B>ULYS, L.L.C.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 247.7pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">By: <U>/s/ Raymond Debbane&#9;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Name: Raymond Debbane</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Title: President</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 247.7pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 247.7pt 0 0"><B>MR. RAYMOND DEBBANE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 247.7pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">By: <U>/s/ Raymond Debbane&#9;</U></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt/107% Arial, Helvetica, Sans-Serif; margin: 0 0 8pt">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
